Gempower 200 Injection contains Gemcitabine 200 mg, a nucleoside analog used as an antineoplastic agent in the treatment of various malignancies. Gemcitabine exerts its cytotoxic effect by incorporating into DNA during the S-phase of the cell cycle, leading to inhibition of DNA synthesis and induction of apoptosis. It is primarily indicated for the management of non-small cell lung cancer, pancreatic cancer, bladder cancer, breast cancer, and ovarian cancer. Gempower 200 Injection is administered intravenously, with dosing regimens tailored according to the specific cancer type, patient condition, and treatment protocol. Common adverse effects include myelosuppression, manifested as neutropenia, thrombocytopenia, and anemia, as well as gastrointestinal disturbances such as nausea, vomiting, and elevated liver enzymes. Hypersensitivity reactions and pulmonary toxicity have also been reported. Prior to administration, baseline hematologic and liver function tests are recommended, with ongoing monitoring throughout therapy. Dose adjustments may be necessary in cases of renal or hepatic impairment. Gempower 200 Injection should be used under strict medical supervision, with appropriate supportive care measures to manage side effects. It is contraindicated in patients with known hypersensitivity to gemcitabine or any of its excipients. Careful consideration of benefit-risk ratio is essential when prescribing this agent.